IDI2

Across TCGA pan-cancer cohorts, IDI2 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated IDI2 data layer compared with 2 for mutation status.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher IDI2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated IDI2 expression acts as an unfavorable survival marker, although some lineages such as LGG and LUAD show a favorable association.

CHOL, LIHC, and ACC are the cancer types where IDI2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.417	0.913	.001	45	view →
LIHC	OS	Tertile	All	0.664	0.814	.005	36	view →
ACC	DFS	Quartile	III,IV	0.158	0.543	.005	35	view →
LGG	OS	Median	All	0.933	0.856	<.001	21	view →
LUAD	OS	Median	III,IV	0.622	0.400	.015	20	view →
SKCM	DFS	Median	IV	0.187	0.763	.006	19	view →
SCLC	DFS	Quartile	All	0.400	0.120	.016	14	view →
LUSC	DFS	Quartile	III,IV	0.167	0.690	.004	14	view →
READ	OS	Median	All	1.000	0.876	.014	14	view →
KICH	OS	Quartile	II,III,IV	0.692	0.932	.017	13	view →
THCA	OS	Tertile	III,IV	0.941	0.979	.020	6	view →
COAD	OS	Tertile	III,IV	0.487	0.723	.049	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

IDI2–CHOL (OS)

Open the CHOL breakdown →